The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma February 23, 2021 by Businesswire [#item_full_content] Related Spread the word